Abstract

Sole Prashant Pandurang*, Hingane Lahu Dnyandev, Jain Santosh Rameshrao and More Sagar Navnath

ABSTRACT

Tyrosine kinases inhibiter nintedanib reduces rate of decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis, other chronic fibrosin interstitial lung disease (ILDS) with a progressive phenotype and systemic sclerosis associated ILD, (SSc-ILD) recommended dose of od nintedanib is 150mg twice a dilly(BID). IPF were analyzed to the investigate relationship between nintedanib plasma concentration (exposure) and efficacy for most patients with chronic fibrosin ILDs, the 150 mg nintedanib (BID) dose provides exposure levels associated with a therapeutic effect close to the maximum nintedanib effect independent of disease condition and baseline demographic.